Victoria Del Gaizo Moore, PhD
Assistant Professor of Chemistry
Ph.D., Molecular Medicine and Translational Science Graduate
Program, May 2004
Wake Forest University Graduate School of Arts
B.S., James Madison University, 1995 - 1999
Del Gaizo Moore V, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol. 2008;615:159-75. Review.
Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15;111(4):2300-9.
Del Gaizo Moore, V., Brown, J.R., Certo, M., Love, T.M., Novina, C.D., and A. Letai. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. JCI, January 2007, 117(1): 112-121.
Certo M., Del Gaizo Moore V., Nishino, M., Wei G., Korsmeyer, S., Armstrong, S.A., and A. Letai. Cellular Addiction to Antiapoptotic BCL-Family Proteins Revealed by Mitochondrial Sensitivity to Sensitizer BH3 Peptides and ABT-737. Cancer Cell, May 2006, 9: 351-365.
Angdison J., Del Gaizo Moore V., Cline J.M. Payne, R.M., and J.A. Ibdah. Mitochondrial Trifunctional Protein Defects: Molecular Basis and Novel Therapeutic Approaches. CTD-IEMD, March 2005: 5(1): 27-40
Del Gaizo Moore, V. and Letai, A. 2006. In press. "Rational Design of Therapeutics Targeting the Bcl-2 family" in Programmed Cell Death in Cancer Progression and Therapy. Springer Publishing.
For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine.
American Cancer Society Post-doctoral Fellowship
“Targeting BCL-2 Addiction in Leukemia”